Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MYO16 antisense RNA 2 (MYO16-AS2) is a long non-coding RNA locus in the human genome. It is transcribed antisense to the protein-coding MYO16 gene, but does not encode a protein. There is currently no experimental evidence for a functional role of this lncRNA or its involvement in any known biological processes or diseases. MYO16-AS2 is not considered a direct therapeutic target, enzyme, transporter, transcription factor, or receptor. No common alternative names or abbreviations other than MYO16-AS2 have been identified[1]. Clarification: - The MYO16-AS2 gene should not be confused with *MYO16* (myosin XVI), which encodes a protein implicated in neuronal development and disease[2][3]. *MYO16* is a distinct entity with a broader functional literature, while *MYO16-AS2* is only annotated as a non-coding RNA transcript with no current evidence for a direct therapeutic or diagnostic role[1]. - There is no evidence of drugs or direct molecular targeting involving MYO16-AS2. Summary: MYO16-AS2 is a non-coding RNA gene, not a druggable target, receptor, or enzyme, and currently lacks evidence for a biological or disease-associated function[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MYO16 antisense RNA 2 (MYO16-AS2).